Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 224

1.

Vertebral Fractures of Unknown Origin: Role of Computed Tomography-Guided Biopsy.

Spinnato P, Bazzocchi A, Facchini G, Filonzi G, Nanni C, Rambaldi I, Rimondi E, Fanti S, Albisinni U.

Int J Spine Surg. 2018 Dec 21;12(6):673-679. doi: 10.14444/5084. eCollection 2018 Dec.

2.

Nuclear Medicine Imaging of Prostate Cancer in the Elderly.

Castellucci P, Nanni C, Ambrosini V.

Semin Nucl Med. 2018 Nov;48(6):541-547. doi: 10.1053/j.semnuclmed.2018.07.004. Epub 2018 Aug 8. Review.

PMID:
30322480
3.

State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer.

Schiavina R, Chessa F, Borghesi M, Gaudiano C, Bianchi L, Corcioni B, Castellucci P, Ceci F, Ceravolo I, Barchetti G, Del Monte M, Campa R, Catalano C, Panebianco V, Nanni C, Fanti S, Minervini A, Porreca A, Brunocilla E.

Int J Urol. 2019 Jan;26(1):18-30. doi: 10.1111/iju.13797. Epub 2018 Sep 20. Review.

PMID:
30238516
4.

Contribution of PET imaging to mortality risk stratification in candidates to lead extraction for pacemaker or defibrillator infection: a prospective single center study.

Diemberger I, Bonfiglioli R, Martignani C, Graziosi M, Biffi M, Lorenzetti S, Ziacchi M, Nanni C, Fanti S, Boriani G.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):194-205. doi: 10.1007/s00259-018-4142-9. Epub 2018 Sep 8.

PMID:
30196365
5.

Prognostic value of posttreatment 18F-FDG PET/CT and predictors of metabolic response to therapy in patients with locally advanced cervical cancer treated with concomitant chemoradiation therapy: an analysis of intensity- and volume-based PET parameters.

Lima GM, Matti A, Vara G, Dondi G, Naselli N, De Crescenzo EM, Morganti AG, Perrone AM, De Iaco P, Nanni C, Fanti S.

Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2139-2146. doi: 10.1007/s00259-018-4077-1. Epub 2018 Aug 2.

6.

In Vivo Imaging of Inflammation and Infection.

Roivainen A, Li XG, Nanni C, Cai W, Ohrndorf S.

Contrast Media Mol Imaging. 2018 May 17;2018:3817871. doi: 10.1155/2018/3817871. eCollection 2018. No abstract available.

7.

Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer.

Schiavina R, Bianchi L, Mineo Bianchi F, Borghesi M, Pultrone CV, Dababneh H, Castellucci P, Ceci F, Nanni C, Gaudiano C, Fiorentino M, Porreca A, Chessa F, Minervini A, Fanti S, Brunocilla E.

Clin Genitourin Cancer. 2018 Aug;16(4):305-312.e1. doi: 10.1016/j.clgc.2018.05.010. Epub 2018 May 30.

PMID:
29859737
8.

Low dose radiation 18F-fluoride PET/CT in the assessment of Unilateral Condylar Hyperplasia of the mandible: preliminary results of a single centre experience.

Lima GM, Diodato S, Costabile E, Cicoria G, Civollani S, Marchetti C, Guidalotti PL, Pettinato C, Nanni C, Fanti S.

Eur J Hybrid Imaging. 2018;2(1):7. doi: 10.1186/s41824-018-0025-3. Epub 2018 Apr 9.

9.

Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report.

Nanni L, Broccoli A, Nanni C, Argnani L, Cavo M, Zinzani PL.

Leuk Lymphoma. 2018 Dec;59(12):2990-2993. doi: 10.1080/10428194.2018.1443336. Epub 2018 Apr 4. No abstract available.

PMID:
29616869
10.

A review discussing fluciclovine (18F) PET/CT imaging in the detection of recurrent prostate cancer.

Zanoni L, Bossert I, Matti A, Schiavina R, Pultrone C, Fanti S, Nanni C.

Future Oncol. 2018 May;14(11):1101-1115. doi: 10.2217/fon-2017-0446. Epub 2018 Jan 23. Review.

PMID:
29359581
11.

Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).

Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, Bellò M, Gallamini A, Patriarca F, Gay F, Gamberi B, Ghedini P, Cavo M, Fanti S, Zamagni E.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):712-719. doi: 10.1007/s00259-017-3909-8. Epub 2017 Dec 21.

PMID:
29270787
12.

FDG-PET/CT Guided Biopsy in Angiosarcoma of Bone: Diagnosis, Staging and Beyond.

Matti A, Farolfi A, Frisoni T, Fanti S, Nanni C.

Clin Nucl Med. 2018 Feb;43(2):e48-e49. doi: 10.1097/RLU.0000000000001918.

PMID:
29215413
13.

Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.

Ghedini P, Bossert I, Zanoni L, Ceci F, Graziani T, Castellucci P, Ambrosini V, Massari F, Nobili E, Melotti B, Musto A, Zoboli S, Antunovic L, Kirienko M, Chiti A, Mosconi C, Ardizzoni A, Golfieri R, Fanti S, Nanni C.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):751-758. doi: 10.1007/s00259-017-3888-9. Epub 2017 Nov 30.

PMID:
29192364
14.

Relation between thoracic aortic inflammation and features of plaque vulnerability in the coronary tree in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. An FDG-positron emission tomography and optical coherence tomography study.

Taglieri N, Nanni C, Ghetti G, Bonfiglioli R, Saia F, Bacchi Reggiani ML, Lima GM, Marco V, Prati F, Fanti S, Rapezzi C.

Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1878-1887. doi: 10.1007/s00259-017-3747-8. Epub 2017 Jun 6.

PMID:
28584972
15.

Therapy assessment in multiple myeloma with PET.

Nanni C, Zamagni E.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):111-117. doi: 10.1007/s00259-017-3730-4. Epub 2017 Jun 1. Review.

PMID:
28573329
16.

A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role?

Filonzi G, Mancuso K, Zamagni E, Nanni C, Spinnato P, Cavo M, Fanti S, Salizzoni E, Bazzocchi A.

AJR Am J Roentgenol. 2017 Jul;209(1):152-158. doi: 10.2214/AJR.16.17219. Epub 2017 Apr 18.

PMID:
28418695
17.

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.

Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E.

Lancet Oncol. 2017 Apr;18(4):e206-e217. doi: 10.1016/S1470-2045(17)30189-4. Review.

PMID:
28368259
18.

Prostate Cancer Imaging in the Era of Molecular Medicine.

Baum RP, Nanni C.

PET Clin. 2017 Apr;12(2):xi. doi: 10.1016/j.cpet.2017.01.001. No abstract available.

PMID:
28267459
19.

Report of the 6th International Workshop on PET in lymphoma.

Nanni C, Cottereau AS, Lopci E, Bodet-Milin C, Coronado M, Pro B, Kim WS, Trotman J, Barrington S, Duhrsen U, Vander Borght T, Zamagni E, Kraeber-Bodéré F, Messiou C, Rahmouni A, Buvat I, Andre M, Hertzberg M, Oyen W, Casasnovas O, Luminari S, Garderet L, Montravers F, Kobe C, Kluge R, Versari A, Zucca E, Moreau P, Cheson B, Haioun C, Gallamini A, Meignan M.

Leuk Lymphoma. 2017 Oct;58(10):2298-2303. doi: 10.1080/10428194.2017.1298752. Epub 2017 Mar 7.

PMID:
28264597
20.

18F-FDG PET/CT scan confirmed by pathology findings in a singular case of squamous cell carcinoma of the epiglottis.

Lima GM, Matti A, Burgio L, Nanni C, Castellucci P, Fanti S.

Eur J Hybrid Imaging. 2017;1(1):1. doi: 10.1186/s41824-017-0012-0. Epub 2017 Nov 15.

21.

Interpretation of 11C-choline PET/CT for the diagnosis of local relapse in radically treated prostate cancer.

Matti A, Lima GM, Zanoni L, Pultrone C, Schiavina R, Lodi F, Fanti S, Nanni C.

Eur J Hybrid Imaging. 2017;1(1):5. doi: 10.1186/s41824-017-0007-x. Epub 2017 Oct 12.

22.

PET Tracers Beyond FDG in Prostate Cancer.

Schuster DM, Nanni C, Fanti S.

Semin Nucl Med. 2016 Nov;46(6):507-521. doi: 10.1053/j.semnuclmed.2016.07.005. Epub 2016 Sep 7. Review.

23.

Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer.

Bach-Gansmo T, Nanni C, Nieh PT, Zanoni L, Bogsrud TV, Sletten H, Korsan KA, Kieboom J, Tade FI, Odewole O, Chau A, Ward P, Goodman MM, Fanti S, Schuster DM, Willoch F.

J Urol. 2017 Mar;197(3 Pt 1):676-683. doi: 10.1016/j.juro.2016.09.117. Epub 2016 Oct 13.

24.

Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs.

Schuster DM, Nanni C, Fanti S.

J Nucl Med. 2016 Oct;57(Suppl 3):61S-66S. Review.

25.

The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.

Palmerini E, Colangeli M, Nanni C, Fanti S, Marchesi E, Paioli A, Picci P, Cambioli S, Donati D, Cevolani L, De Paolis M, Gambarotti M, Ferrari S.

Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):215-223. doi: 10.1007/s00259-016-3509-z. Epub 2016 Sep 20.

26.

PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer.

Ceci F, Castellucci P, Nanni C, Fanti S.

Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2103-2104. No abstract available.

PMID:
27557847
27.

The Possible Role of PET Imaging Toward Individualized Management of Bone and Soft Tissue Malignancies.

Tabacchi E, Fanti S, Nanni C.

PET Clin. 2016 Jul;11(3):285-96. doi: 10.1016/j.cpet.2016.02.011. Epub 2016 Mar 18. Review.

PMID:
27321032
28.

Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT?

Gagliardi C, Tabacchi E, Bonfiglioli R, Diodato S, Nanni C, Guidalotti P, Lorenzini M, Lodi F, Milandri A, Rapezzi C, Fanti S.

J Nucl Cardiol. 2017 Apr;24(2):746-749. doi: 10.1007/s12350-016-0457-8. Epub 2016 Mar 14.

PMID:
26976144
29.

(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.

Nanni C, Zanoni L, Pultrone C, Schiavina R, Brunocilla E, Lodi F, Malizia C, Ferrari M, Rigatti P, Fonti C, Martorana G, Fanti S.

Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1601-10. doi: 10.1007/s00259-016-3329-1. Epub 2016 Mar 10.

PMID:
26960562
30.

Engineered porphyrin loaded core-shell nanoparticles for selective sonodynamic anticancer treatment.

Varchi G, Foglietta F, Canaparo R, Ballestri M, Arena F, Sotgiu G, Guerrini A, Nanni C, Cicoria G, Cravotto G, Fanti S, Serpe L.

Nanomedicine (Lond). 2015;10(23):3483-94. doi: 10.2217/nnm.15.150. Epub 2015 Nov 26.

31.

18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.

Zamagni E, Nanni C, Gay F, Pezzi A, Patriarca F, Bellò M, Rambaldi I, Tacchetti P, Hillengass J, Gamberi B, Pantani L, Magarotto V, Versari A, Offidani M, Zannetti B, Carobolante F, Balma M, Musto P, Rensi M, Mancuso K, Dimitrakopoulou-Strauss A, Chauviè S, Rocchi S, Fard N, Marzocchi G, Storto G, Ghedini P, Palumbo A, Fanti S, Cavo M.

Leukemia. 2016 Feb;30(2):417-22. doi: 10.1038/leu.2015.291. Epub 2015 Oct 22.

PMID:
26490489
32.

Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).

Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, Bellò M, Rambaldi I, Gallamini A, Patriarca F, Gay F, Gamberi B, Cavo M, Fanti S.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):414-21. doi: 10.1007/s00259-015-3200-9. Epub 2015 Oct 16.

PMID:
26475305
33.

Heterogeneous response of cardiac sympathetic function to cardiac resynchronization therapy in heart failure documented by 11[C]-hydroxy-ephedrine and PET/CT.

Capitanio S, Nanni C, Marini C, Bonfiglioli R, Martignani C, Dib B, Fuccio C, Boriani G, Picori L, Boschi S, Morbelli S, Fanti S, Sambuceti G.

Nucl Med Biol. 2015 Nov;42(11):858-63. doi: 10.1016/j.nucmedbio.2015.07.002. Epub 2015 Jul 8.

PMID:
26239084
34.

PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.

Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L, Zannetti B, Rambaldi I, Brioli A, Rocchi S, Terragna C, Martello M, Marzocchi G, Borsi E, Rizzello I, Fanti S, Cavo M.

Clin Cancer Res. 2015 Oct 1;21(19):4384-90. doi: 10.1158/1078-0432.CCR-15-0396. Epub 2015 Jun 15.

35.

18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.

Nanni C, Schiavina R, Brunocilla E, Boschi S, Borghesi M, Zanoni L, Pettinato C, Martorana G, Fanti S.

Clin Nucl Med. 2015 Aug;40(8):e386-91. doi: 10.1097/RLU.0000000000000849.

PMID:
26053708
36.

Cardiac resynchronization therapy and cardiac sympathetic function.

Martignani C, Diemberger I, Nanni C, Biffi M, Ziacchi M, Boschi S, Corzani A, Fanti S, Sambuceti G, Boriani G.

Eur J Clin Invest. 2015 Aug;45(8):792-9. doi: 10.1111/eci.12471. Epub 2015 Jul 3.

PMID:
26036750
37.

The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.

Patriarca F, Carobolante F, Zamagni E, Montefusco V, Bruno B, Englaro E, Nanni C, Geatti O, Isola M, Sperotto A, Buttignol S, Stocchi R, Corradini P, Cavo M, Fanin R.

Biol Blood Marrow Transplant. 2015 Jun;21(6):1068-73. doi: 10.1016/j.bbmt.2015.03.001. Epub 2015 Mar 6.

38.

FDG PET/CT for bone and soft-tissue biopsy.

Nanni C, Gasbarrini A, Cappelli A, Sandler I, Graziani T, Guidalotti P, Golfieri R, Boriani S, Fanti S.

Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1333-4. doi: 10.1007/s00259-015-3017-6. Epub 2015 Feb 19. No abstract available.

PMID:
25693761
39.

Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP).

Ambrosini V, Morigi JJ, Nanni C, Castellucci P, Fanti S.

Q J Nucl Med Mol Imaging. 2015 Mar;59(1):58-69. Epub 2015 Feb 12. Review.

PMID:
25677589
40.

Imaging biomarkers in prostate cancer: role of PET/CT and MRI.

Picchio M, Mapelli P, Panebianco V, Castellucci P, Incerti E, Briganti A, Gandaglia G, Kirienko M, Barchetti F, Nanni C, Montorsi F, Gianolli L, Fanti S.

Eur J Nucl Med Mol Imaging. 2015 Apr;42(4):644-55. doi: 10.1007/s00259-014-2982-5. Epub 2015 Jan 17. Review.

PMID:
25595344
41.

Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease.

Schuster DM, Nanni C, Fanti S, Oka S, Okudaira H, Inoue Y, Sörensen J, Owenius R, Choyke P, Turkbey B, Bogsrud TV, Bach-Gansmo T, Halkar RK, Nye JA, Odewole OA, Savir-Baruch B, Goodman MM.

J Nucl Med. 2014 Dec;55(12):1986-92. doi: 10.2967/jnumed.114.143628. Epub 2014 Nov 13.

42.

Nuclear medicine in urological cancers: what is new?

Nanni C, Zanoni L, Fanti S.

Future Oncol. 2014 Oct;10(13):2061-72. doi: 10.2217/fon.14.87. Review.

PMID:
25396777
43.

First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection.

Brunocilla E, Schiavina R, Nanni C, Borghesi M, Cevenini M, Molinaroli E, Vagnoni V, Castellucci P, Ceci F, Fanti S, Gaudiano C, Golfieri R, Martorana G.

Arch Ital Urol Androl. 2014 Sep 30;86(3):239-40. doi: 10.4081/aiua.2014.3.239.

44.

Antiinflammatory effect of phytosterols in experimental murine colitis model: prevention, induction, remission study.

Aldini R, Micucci M, Cevenini M, Fato R, Bergamini C, Nanni C, Cont M, Camborata C, Spinozzi S, Montagnani M, Roda G, D'Errico-Grigioni A, Rosini F, Roda A, Mazzella G, Chiarini A, Budriesi R.

PLoS One. 2014 Sep 30;9(9):e108112. doi: 10.1371/journal.pone.0108112. eCollection 2014.

45.

In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.

Hutchings M, Kostakoglu L, Zaucha JM, Malkowski B, Biggi A, Danielewicz I, Loft A, Specht L, Lamonica D, Czuczman MS, Nanni C, Zinzani PL, Diehl L, Stern R, Coleman M.

J Clin Oncol. 2014 Sep 1;32(25):2705-11. doi: 10.1200/JCO.2013.53.2838. Epub 2014 Jul 28.

PMID:
25071108
46.

The use of gallium-68 labeled somatostatin receptors in PET/CT imaging.

Ambrosini V, Nanni C, Fanti S.

PET Clin. 2014 Jul;9(3):323-9. doi: 10.1016/j.cpet.2014.03.008. Epub 2014 Apr 26. Review.

PMID:
25030395
47.

11C-mHED for PET / CT: principles of synthesis, methodology and first clinical applications.

Bonfiglioli R, Nanni C, Martignani C, Zanoni L, La Donna R, Diemberger I, Boriani G, Pettinato C, Sambuceti G, Fanti S, Mansi L.

Curr Radiopharm. 2014;7(2):79-83. Review.

PMID:
25022366
48.

11C-meta-hydroxyephedrine: a promising PET radiopharmaceutical for imaging the sympathetic nervous system.

Boschi S, Lodi F, Boschi L, Nanni C, Chondrogiannis S, Colletti PM, Rubello D, Fanti S.

Clin Nucl Med. 2015 Feb;40(2):e96-e103. doi: 10.1097/RLU.0000000000000512. Review.

PMID:
24999701
49.

PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.

Lopci E, Grassi I, Chiti A, Nanni C, Cicoria G, Toschi L, Fonti C, Lodi F, Mattioli S, Fanti S.

Am J Nucl Med Mol Imaging. 2014 Jun 7;4(4):365-84. eCollection 2014. Review.

50.

Pretherapeutic dosimetry in patients affected by metastatic thyroid cancer using 124I PET/CT sequential scans for 131I treatment planning.

Pettinato C, Spezi E, Nanni C, Grassetto G, Monari F, Allegri V, Civollani S, Cima S, Zagni P, Mazzarotto R, Colletti PM, Rubello D, Fanti S.

Clin Nucl Med. 2014 Aug;39(8):e367-74. doi: 10.1097/RLU.0000000000000490.

PMID:
24978332

Supplemental Content

Support Center